Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Recruiting Phase 1Phase 2 Interventional

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

ClinicalTrials.gov ID: NCT04094610

Public ClinicalTrials.gov record NCT04094610. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2, Open-label, Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK1-3 Alterations (CARE)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) and select the Pediatric Recommended Phase 2 Dose (RP2D). Phase 2 will determine the anti-tumor activity of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring ROS1 or NTRK1-3 alterations.

Study identification

NCT ID
NCT04094610
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1, Phase 2
Enrollment
75 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
Up to 25 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 12, 2020 (Actual)
Primary completion
Sep 30, 2026 (Estimated)
Completion
Sep 30, 2027 (Estimated)
Last update posted
Sep 25, 2026

2020 – 2027

United States locations

U.S. sites
20
U.S. states
15
U.S. cities
17
Facility City State ZIP Site status
Children's Hospital Los Angeles Los Angeles California 90027-6062 Recruiting
University of California at Los Angeles Los Angeles California 90095 Recruiting
Children's Hospital Colorado - Anschutz Medical Campus Aurora Colorado 80045 Recruiting
Local Institution - 2105 Orlando Florida 32806 Completed
Local Institution - 2120 Orlando Florida 32827 Completed
Children's Healthcare of Atlanta - Egleston Hospital Atlanta Georgia 30329 Recruiting
Maine Medical Center Scarborough Maine 04074 Recruiting
Dana Farber Cancer Institute. Boston Massachusetts 02215 Recruiting
Washington University School of Medicine in St. Louis St Louis Missouri 63110 Recruiting
Local Institution - 2110 New Brunswick New Jersey 08901 Completed
Local Institution - 2102 New York New York 10065 Completed
Levine Children's Hospital- Pediatric Neuro-Oncology Charlotte North Carolina 28203 Recruiting
Local Institution - 2112 Cleveland Ohio 44195 Completed
Local Institution - 2114 Hershey Pennsylvania 17033 Completed
Children's Hospital of Philadelphia-Center for Childhood Cancer Research Philadelphia Pennsylvania 19104 Recruiting
St. Jude Children's Research Hospital Memphis Tennessee 38015 Recruiting
The University of Texas Southwestern Medical Center - Harold C Simmons Comprehensive Cancer Center Dallas Texas 75390 Recruiting
Baylor College of Medicine Houston Texas 77030 Recruiting
Local Institution - 2104 Houston Texas 77030 Completed
Children's Hospital of Richmond at VCU Richmond Virginia 23219 Withdrawn

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 48 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04094610, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 25, 2026 · Synced Oct 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04094610 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →